HIMS vs. NTRA, GH, RDNT, OPCH, SHC, BTSG, WGS, CON, SGRY, and PRVA
Should you be buying Hims & Hers Health stock or one of its competitors? The main competitors of Hims & Hers Health include Natera (NTRA), Guardant Health (GH), RadNet (RDNT), Option Care Health (OPCH), Sotera Health (SHC), BrightSpring Health Services (BTSG), GeneDx (WGS), Concentra Group Holdings Parent (CON), Surgery Partners (SGRY), and Privia Health Group (PRVA). These companies are all part of the "healthcare" industry.
Hims & Hers Health vs. Its Competitors
Hims & Hers Health (NYSE:HIMS) and Natera (NASDAQ:NTRA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.
63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 17.7% of Hims & Hers Health shares are held by company insiders. Comparatively, 5.6% of Natera shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Hims & Hers Health has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500. Comparatively, Natera has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500.
Hims & Hers Health has a net margin of 9.63% compared to Natera's net margin of -12.89%. Hims & Hers Health's return on equity of 26.26% beat Natera's return on equity.
In the previous week, Hims & Hers Health had 56 more articles in the media than Natera. MarketBeat recorded 89 mentions for Hims & Hers Health and 33 mentions for Natera. Natera's average media sentiment score of 1.01 beat Hims & Hers Health's score of 0.31 indicating that Natera is being referred to more favorably in the news media.
Hims & Hers Health presently has a consensus target price of $38.92, indicating a potential downside of 10.48%. Natera has a consensus target price of $193.19, indicating a potential upside of 20.26%. Given Natera's stronger consensus rating and higher probable upside, analysts clearly believe Natera is more favorable than Hims & Hers Health.
Hims & Hers Health has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.
Summary
Hims & Hers Health beats Natera on 10 of the 17 factors compared between the two stocks.
Get Hims & Hers Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HIMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hims & Hers Health Competitors List
Related Companies and Tools
This page (NYSE:HIMS) was last updated on 8/20/2025 by MarketBeat.com Staff
MarketBeat All Access